Xeris Biopharma Holdings, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 20.43M49.59M110.25M163.91M203.07M
Cost of Revenue 9.33M13.32M22.63M28.64M36.83M
Gross Profit 11.11M36.27M87.61M135.27M166.24M
Operating items
Amortization - Intangibles 0.55M10.84M10.84M10.84M
Research & Development 20.92M25.16M20.97M22.34M25.56M
Selling, General & Administrative 73.73M125.72M137.75M146.09M163.48M
Other Operating Expenses 9.33M13.87M33.48M39.49M47.67M
Operating Expenses 103.98M164.75M192.19M207.92M236.72M
Operating Income -83.55M-115.16M-81.94M-44.01M-33.65M
EBIT -83.55M-115.16M-81.94M-44.01M-33.65M
Non-operating items
Interest & Investment Income 2.96M0.31M2.58M4.75M5.32M
Other Non Operating Income -7.70M-7.57M-14.14M-19.49M-23.46M
Non Operating Income -7.70M-7.57M-14.14M-19.49M-23.46M
Net income details
EBT -91.25M-122.72M-96.08M-63.50M-57.10M
Tax Provisions -0.11M-1.42M-1.25M-2.27M
Profit After Tax -91.14M-122.72M-94.66M-62.26M-54.84M
Income from Continuing Operations -91.14M-122.72M-94.66M-62.26M-54.84M
Consolidated Net Income -91.14M-122.72M-94.66M-62.26M-54.84M
Income towards Parent Company -91.14M-122.72M-94.66M-62.26M-54.84M
Net Income towards Common Stockholders -91.14M-122.72M-94.66M-62.26M-54.84M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 48.98M124.71M135.99M138.12M149.08M
Shares Outstanding (Diluted Average) 79.03M135.63M137.67M146.77M
EBITDA -91.18M-122.76M-94.65M-62.26M-54.84M
Tax Rate 0.12%1.48%1.97%3.97%